Anna Maria Di Giacomo

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 986 citations

Medicine, Advanced Brafv600-mutant Melanoma, Melanoma +7

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Benjamin Weide, Alexander Martens, Jessica C. Hassel et al. · Clinical Cancer Research · 2016 · 569 citations · Full text

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba‐Hamprecht, Marnix Geukes Foppen et al. · Clinical Cancer Research · 2016 · 534 citations · Full text

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto et al. · The Lancet Oncology · 2017 · 482 citations · Full text

Oncology, Binimetinib Versus Dacarbazine, Medicine +7